Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Vincristine Sulfate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Introducing Vicrista® – A New Era in Pediatric Oncology
Details : Vicrista (vincristine sulphate) is a type of chemotherapy called a vinca alkaloid which interfere with microtubules and blocks cell growth by stopping mitosis. It is indicated for pediatric cancers.
Product Name : Vicrista
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
November 03, 2024
Lead Product(s) : Vincristine Sulfate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brentuximab Vedotin,Doxorubicin Hydrochloride,Vincristine Sulfate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ADCETRIS (brentuximab vedotin) is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seagen’s proprietary tec...
Product Name : Adcetris
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
November 11, 2022
Lead Product(s) : Brentuximab Vedotin,Doxorubicin Hydrochloride,Vincristine Sulfate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vincristine Sulfate,Carboplatin,Etoposide
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : $0.7 million
Deal Type : Funding
Funding Secured For UK Clinical Trial in Children With Neuroblastoma
Details : The ten year SIOPEN High-Risk Neuroblastoma Clinical Trial 2 (HR-NBL2) is a Phase III clinical trial designed to evaluate potential treatment pathways for children identified with the disease.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
May 21, 2020
Lead Product(s) : Vincristine Sulfate,Carboplatin,Etoposide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : $0.7 million
Deal Type : Funding
Lead Product(s) : Vincristine Sulfate
Therapeutic Area : Hematology
Study Phase : Phase I
Sponsor : Axis Clinicals Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
January 28, 2020
Lead Product(s) : Vincristine Sulfate
Therapeutic Area : Hematology
Highest Development Status : Phase I
Sponsor : Axis Clinicals Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vincristine Sulfate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Spectrum Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Marqibo
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
August 26, 2016
Lead Product(s) : Vincristine Sulfate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Spectrum Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vincristine Sulfate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : National Cancer Institute | Spectrum Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
January 13, 2015
Lead Product(s) : Vincristine Sulfate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : National Cancer Institute | Spectrum Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vincristine Sulfate
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Gangneung Asan Hospital | Guangdong Provincial People's Hospital | Qilu Hospital of Shandong University | Xijing Hospital | Xinqiao Hospital, Chongqing | China Medical University, China | West China Hospital | Second Affiliated Hospital of Xi’an Jiaotong
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
February 27, 2014
Lead Product(s) : Vincristine Sulfate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Gangneung Asan Hospital | Guangdong Provincial People's Hospital | Qilu Hospital of Shandong University | Xijing Hospital | Xinqiao Hospital, Chongqing | China Medical University, China | West China Hospital | Second Affiliated Hospital of Xi’an Jiaotong
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vincristine Sulfate
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 14, 2014
Lead Product(s) : Vincristine Sulfate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vincristine Sulfate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
May 10, 2013
Lead Product(s) : Vincristine Sulfate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vincristine Sulfate
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : German High-Grade NHL Study Group | Spectrum Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 23, 2011
Lead Product(s) : Vincristine Sulfate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : German High-Grade NHL Study Group | Spectrum Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable